This scenario would be in line with recent studies demonstrating that an inhibitor of CCL2 synthesis protects neurons against Abeta toxicity [57] and that inhibition of microglial activation reduces cognitive deficits in a transgenic mouse model for AD [5]. Here, APP is linked to Alzheimer disease.